8-K 1 azurrx8k.htm CURRENT REPORT 8-K
 
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 12, 2018
 
 
AZURRX BIOPHARMA, INC.
 
(Exact name of Registrant as specified in its Charter)
 
 
 
 
 
Delaware
001-37853
46-4993860
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer
Identification No.)
 
 
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, New York
 
 
11226
(Address of principal executive offices)               
(Zip Code)
 
 
Registrant’s telephone number, including area code: (646) 699-7855
(Name, address, including zip code, and telephone number, including area code, of agent for service of process)
 
NOT APPLICABLE
(Former Name or Former Address, if Changes Since Last Report)
 
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2) ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
 

 
 
 
 
Item 7.01                Regulation FD Disclosure
 
On February 12, 2018, AzurRx BioPharma, Inc. (the “Company”) presented at the 2018 BIO CEO & Investor Conference in New York City at the Marriot Marquis, utilizing a new corporate presentation (the “Corporate Presentation”), a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8K, and is incorporated by reference herein.  
 
Item 8.01                Other Events
 
On February 12, 2018, the Company issued a press release announcing its enrollment of three new patients for its phase IIa study of MS1819 for patients with exocrine pancreatic insufficiency caused by chronic pancreatitis, which patients were enrolled in sites in Australia, bringing the total number of patients dosed in the trial to nine.  A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated by reference herein.
 
Disclaimer.
 
The information in Item 7.01 of this Current Report on Form 8K, including the information set forth in Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01                Financial Statements and Exhibits.
 
See Exhibit Index.
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
AzurRx BioPharma, Inc.
 
Date:   February 12, 2018
 
 
   
By: /s/ Johan M. Spoor
Name: Johan M. Spoor
Title: Chief Executive Officer
 
 
 
 
 
 
Exhibit Index
 
Exhibit Number
  
Description
 
 
  
Corporate Presentation, dated February 2018
  
Press Release, dated February 12, 2018